ABcann Medicinals Inc (ABCN)

[NetworkNewsWire]

ABCN Names Barry Fishman as New CEO

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced the appointment of Barry Fishman as its new chief executive officer, effective October 1, 2017. Fishman brings nearly two decades of experience as a business leader to the ABcann team, having most recently served as CEO of international specialty pharmaceutical company Merus Labs. Under his leadership, Merus’s sales and EBITDA grew at a CAGR of greater than 50 percent, leading to the company’s acquisition by Norgine B.V. in July 2017 for total considerations of roughly $342 million. “Barry’s proven experience as a CEO of complex, highly-regulated organizations with international operations will serve ABcann and our shareholders well as we continue to execute our growth strategy, including the significant expansion of our production capacity, and establishing our unique leadership position in the cannabis industry,” Ken Clement, executive chairman of ABcann, stated in the news release. “We would also like to take this opportunity to thank Aaron Keay for the committed and dedicated work he has done positioning ABcann within the capital markets and we look forward to his continued active involvement with the Company, including serving on our Board of Directors.”

To view the full press release, visit http://nnw.fm/sOm1r

About ABcann Global Corporation

ABcann Global Corporation’s wholly owned subsidiary, ABcann Medicinals Inc., was one of the first companies to obtain a production license under the Marijuana for Medical Purposes Regulations, which it received on March 21, 2014. It obtained a sales license on December 31, 2015. ABcann’s flagship facility in Napanee, Ontario utilizes proprietary plant-growing technology, including environmentally-controlled chambers capable of monitoring and regulating all variables in the growing process. This approach and the systems in place allow ABcann to produce organically grown and pesticide-free, high-yielding plants, which, in turn, can generate high-quality products that are consistent from batch to batch. ABcann is able to control environmental and nutrient demands, tailor-made for a particular strain of cannabis, without the variation that is typical when producing large quantities in less-controlled, larger rooms and greenhouse-type structures. ABcann’s modular approach to systems technology eliminates scale-up risk and allows ABcann to locate anywhere in the world and maintain consistency and quality of product.